The USA-based company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101.

This drug, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.

In June 2022, Mineralys announced the completion of an oversubscribed and up-sized $118 million Series B financing.